Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 plus regorafenib in previously treated metastatic MSS colorectal cancer
NL-OMON45600Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab and regorafenib in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Novartis. Planned start Jun 2017; status: withdrawn.
02
Drugs
spartalizumabregorafenib
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON45600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45600.